keyword
MENU ▼
Read by QxMD icon Read
search

melanoma remission

keyword
https://www.readbyqxmd.com/read/29145317/complete-remission-and-long-term-survival-of-a-patient-with-melanoma-metastases-treated-with-high-dose-fever-inducing-viscum-album-extract-a-case-report
#1
Paul G Werthmann, Alexander Hintze, Gunver S Kienle
INTRODUCTION: Metastatic malignant cutaneous melanoma (MCM)-a highly immunogenic cancer-typically has a poor prognosis. Viscum album extracts (VAEs) have strong immune-stimulating, apoptogenic, and cytotoxic effects. CASE PRESENTATION: A 66-year-old MCM patient with newly diagnosed lymph node metastases opted for sole VAE treatment. VAEs were initially applied subcutaneously, and then later in exceptionally high, fever-inducing doses, both intravenously and intralesionally...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29138980/cd28-neg-t-lymphocytes-of-a-melanoma-patient-harbor-tumor-immunity-and-a-high-frequency-of-germline-encoded-and-public-tcrs
#2
Hisayoshi Hashimoto, Marco Sterk, Karin Schilbach
Increased numbers of CD8(+)CD28(neg.) T cells have been detected in the peripheral blood of patients with several types of malignancies. However, the role of these cells in anticancer immunity are not yet clear and CD8(+)CD28(neg.) T cells are a controversially discussed subpopulation reported both as immunosuppressive and cytotoxic. In this study, we examined the T cell receptor (TCR) repertoire and complementarity-determining region 3 sequences of CD28(neg.) T cells in a melanoma patient with recurrent disease who achieved long-term disease-free status...
November 14, 2017: Immunologic Research
https://www.readbyqxmd.com/read/29124281/absolute-number-of-new-lesions-on-18-f-fdg-pet-ct-is-more-predictive-of-clinical-response-than-suv-changes-in-metastatic-melanoma-patients-receiving-ipilimumab
#3
Hoda Anwar, Christos Sachpekidis, Julia Winkler, Annette Kopp-Schneider, Uwe Haberkorn, Jessica C Hassel, Antonia Dimitrakopoulou-Strauss
PURPOSE: Evaluation of response to immunotherapy is a matter of debate. The aim of the present study was to evaluate the response of metastatic melanoma to treatment with ipilimumab by means of (18)F-FDG PET/CT, using the patients' clinical response as reference. METHODS: The final cohort included in the analyses consisted of 41 patients with metastatic melanoma who underwent (18)F-FDG PET/CT before and after administration of ipilimumab. After determination of the best clinical response, the PET/CT scans were reviewed and a separate independent analysis was performed, based on the number and functional size of newly emerged (18)F-FDG-avid lesions, as well as on the SUV changes after therapy...
November 10, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29114741/factors-associated-with-clinical-remission-of-skin-disease-in-dermatomyositis
#4
Paige W Wolstencroft, Lorinda Chung, Shufeng Li, Livia Casciola-Rosen, David F Fiorentino
Importance: Cutaneous disease represents a significant burden for patients with dermatomyositis. However, quantitative estimates of the probability of skin disease remission and clinical factors associated with skin outcomes are lacking. Objective: To characterize cutaneous disease course in adult patients with dermatomyositis. Design, Setting, and Participants: Prospective cohort study conducted at a dermatology clinic at a tertiary academic referral center...
November 7, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/29114389/adoptive-cell-therapy-with-cd4-t-helper-1-cells-and-cd8-cytotoxic-t-cells-enhances-complete-rejection-of-an-established-tumour-leading-to-generation-of-endogenous-memory-responses-to-non-targeted-tumour-epitopes
#5
Kunyu Li, Braeden Donaldson, Vivienne Young, Vernon Ward, Christopher Jackson, Margaret Baird, Sarah Young
The results of adoptive T-cell therapies (ACTs) are very encouraging and show clinical evidence that ACT can provide a cure for patients with metastatic disease. However, various response rates and long-term cancer remission have been observed in different ACT trials. The types of T cells, prior treatment with chemotherapy and co-administration of other immune-target therapies have been found to influence the efficacy of ACT. In this study, we investigate the ability of ACT using CD4(+) T helper 1 (Th1) cells and CD8(+) cytotoxic T lymphocytes (CTLs) to reject the growth of established B16-ovalbumin (OVA) melanoma...
October 2017: Clinical & Translational Immunology
https://www.readbyqxmd.com/read/29110637/constitutional-mutation-in-cdkn2a-is-associated-with-long-term-survivorship-in-multiple-myeloma-a-case-report
#6
Vallari Shah, Kevin D Boyd, Richard S Houlston, Martin F Kaiser
BACKGROUND: Multiple Myeloma is a cancer of plasma cells associated with significantly reduced survival. Long term survivorship from myeloma is very rare and despite advances in its treatment the disease is generally considered incurable. We report a patient diagnosed with myeloma carrying a germline mutation of a tumour suppressor gene who has effectively been cured. CASE PRESENTATION: A 36-year-old woman was diagnosed with IgG lambda myeloma in 1985. She was treated with melphalan chemotherapy followed by high-dose melphalan and autologous stem cell rescue and since remained in complete remission despite not having received any additional therapy...
November 6, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29094091/ipilimumab-in-pretreated-patients-with-advanced-malignant-melanoma-results-of-the-south-african-expanded-access-program
#7
Bernardo L Rapoport, Daniel A Vorobiof, Lydia M Dreosti, Adam Nosworthy, Georgina McAdam, Johan P Jordaan, Helen Miller-Jansön, Margreet de Necker, Janetta C de Beer, Hennie Duvenhage
Purpose: The primary objective of this study was to evaluate 1- and 2-year survival rates and durable remissions in pretreated patients with advanced (unresectable or metastatic) malignant melanoma treated with ipilimumab in a South African expanded-access program (SA-EAP). Patients and Methods: This multicenter, retrospective study obtained data from pretreated patients with advanced malignant melanoma who were eligible for the ipilimumab SA-EAP. Ipilimumab was administered at a dose of 3 mg/kg intravenously every 3 weeks for four cycles to adults with advanced melanoma for whom at least one line of treatment for metastatic disease had failed...
October 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/29052782/clinical-and-immunologic-evaluation-of-three-metastatic-melanoma-patients-treated-with-autologous-melanoma-reactive-tcr-transduced-t-cells
#8
Tamson Moore, Courtney Regan Wagner, Gina M Scurti, Kelli A Hutchens, Constantine Godellas, Ann Lau Clark, Elizabeth Motunrayo Kolawole, Lance M Hellman, Nishant K Singh, Fernando A Huyke, Siao-Yi Wang, Kelly M Calabrese, Heather D Embree, Rimas Orentas, Keisuke Shirai, Emilia Dellacecca, Elizabeth Garrett-Mayer, Mingli Li, Jonathan M Eby, Patrick J Stiff, Brian D Evavold, Brian M Baker, I Caroline Le Poole, Boro Dropulic, Joseph I Clark, Michael I Nishimura
Malignant melanoma incidence has been increasing for over 30 years, and despite promising new therapies, metastatic disease remains difficult to treat. We describe preliminary results from a Phase I clinical trial (NCT01586403) of adoptive cell therapy in which three patients received autologous CD4(+) and CD8(+) T cells transduced with a lentivirus carrying a tyrosinase-specific TCR and a marker protein, truncated CD34 (CD34t). This unusual MHC Class I-restricted TCR produces functional responses in both CD4(+) and CD8(+) T cells...
October 20, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29041990/piceatannol-induced-apoptosis-through-up-regulation-of-microrna-181a-in-melanoma-cells
#9
Maotao Du, Zhong Zhang, Tao Gao
BACKGROUND: Melanoma took top position among the lethal cancers and, despite there have been some great attempts made to increase the natural life of patients with metastatic disease, long-lasting and complete remissions are few. Piceatannol, owns the similar function as resveratrol, has been defined as an anti-cancer agent playing important role in inhibition of proliferation, migration and metastasis in various cancer. Thus, we aim to investigate the anti-cancer effect and mechanisms of piceatannol in melanoma cells...
October 17, 2017: Biological Research
https://www.readbyqxmd.com/read/29033936/coinhibitory-receptor-expression-and-immune-checkpoint-blockade-maintaining-a-balance-in-cd8-t-cell-responses-to-chronic-viral-infections-and-cancer
#10
REVIEW
Isobel S Okoye, Michael Houghton, Lorne Tyrrell, Khaled Barakat, Shokrollah Elahi
In cancer and chronic viral infections, T cells are exposed to persistent antigen stimulation. This results in expression of multiple inhibitory receptors also called "immune checkpoints" by T cells. Although these inhibitory receptors under normal conditions maintain self-tolerance and prevent immunopathology, their sustained expression deteriorates T cell function: a phenomenon called exhaustion. Recent advances in cancer immunotherapy involve blockade of cytotoxic T lymphocyte antigen-4 and programmed cell death 1 in order to reverse T cell exhaustion and reinvigorate immunity, which has translated to dramatic clinical remission in many cases of metastatic melanoma and lung cancer...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28982291/intranasal-melanoma-treated-with-radiation-therapy-in-three-dogs
#11
Owen Davies, Sarah Spencer, Slavomira Necova, Emma Holmes, Angela Taylor, Laura Blackwood, Ana Lara-Garcia
Three dogs were investigated for chronic unilateral nasal discharge. In all cases CT imaging showed an intranasal mass causing turbinate lysis and no evidence of metastasis. Cytology in cases 1 (a 14-year-old neutered male crossbreed dog) and 2 (a five-year-old neutered male German Shepherd dog) demonstrated a pleomorphic cell population with variable intracellular pigment suspicious of melanocytic neoplasia. Histopathology with immunohistochemistry (Melan-A and vimentin, plus PNL-2 in one case) confirmed the diagnosis of melanoma in all dogs...
October 6, 2017: Veterinary Quarterly
https://www.readbyqxmd.com/read/28945661/second-neoplasms-in-children-following-a-treatment-for-acute-leukemia-and-or-lymphoma-29-years-of-experience-in-a-single-institution-in-argentina
#12
María S Felice, Jorge G Rossi, Cristina N Alonso, Patricia Rubio, Marta S Gallego, María L Galluzzo, Fabiana Lubieniecki, Gladys Gutiérrez, Myriam R Guitter, Daniel H Alderete, Adriana B Rose, Walter D Cacciavillano, Viviana Herzovich, Elizabeth M Alfaro, Cristian G Sánchez La Rosa, Natalia Millán, Guillermo L Chantada, Carlos M Figueroa Turienzo, Pedro A Zubizarreta
INTRODUCTION: Childhood acute leukemias (AL) and lymphomas achieve good survival rates. However, second neoplasms (SN) are a devastating event. METHODS: From August 1987 to December 2016, 34 of 3321 (1%) patients with diagnosis of AL or lymphoma developed SN. SN were AL (n=16), CNS tumors (n=5), endocrinal tumors (n=3), lymphomas (n=2), schwannoma (n=2) assorted sarcomas (n=4), retinal melanoma (n=1), and Vanek tumor (n=1). Median latency was 51 (range, 10 to 110) months for hematological malignancies and 119 (range, 25 to 236) months for solid tumors (P=0...
November 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28944501/synergistic-effects-of-interferon-beta-and-nivolumab-in-oral-mucosal-melanoma
#13
Takayuki Fusumae, Koji Kamiya, Binluen Chiang, Hirofumi Okada, Naomi Nakano, Takeo Maekawa, Mayumi Komine, Satoru Murata, Mamitaro Ohtsuki
Mucosal melanoma is a rare aggressive cancer with a very poor prognosis. Clinical and pathological characteristics of mucosal melanoma differ from those of cutaneous melanoma and there are no established management guidelines for mucosal melanoma. Complete surgical excision is one of the most effective treatments for localized lesions, while targeted therapies and immunotherapies, such as monoclonal antibodies that target cytotoxic T-lymphocyte-associated molecule-4, and the programmed death (PD)-1/PD-ligand 1 pathway inhibitors, are treatment options for unresectable or metastatic lesions...
September 25, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28940544/chronic-granulomatous-dermatitis-induced-by-talimogene-laherparepvec-therapy-of-melanoma-metastases
#14
Ashlyn S Everett, Peter G Pavlidakey, Carlo M Contreras, Jennifer F De Los Santos, Ju Y Kim, Svetlana B McKee, Howard L Kaufman, Robert M Conry
Talimogene laherparepvec is the first oncolytic viral immunotherapy approved by the FDA, for advanced melanoma consisting of genetically modified herpes simplex type 1 virus which selectively replicates causing tumor lysis, expressing GM-CSF and activating dendritic cells. Intratumoral injection of TVEC produces objective response in 41% of stage IIB-IV M1a melanoma. However, clinical response assessments can be problematic due to immune-related inflammation at established tumor sites. Herein, we report 5 cases of granulomatous dermatitis developing at sites of TVEC injection associated with pathologic complete response in 4 of 5 patients...
September 22, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28923120/high-dose-interleukin-2-hd-il-2-for-advanced-melanoma-a-single-center-experience-from-the-university-of-pittsburgh-cancer-institute
#15
Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A Tarhini, John M Kirkwood, Hussein A Tawbi
BACKGROUND: Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% respectively. Toxicity limited use to specialized centers with standardized protocols. We report on 243 patients treated at the University of Pittsburgh in a non-intensive care unit (ICU) oncology specialty setting. METHODS: Clinical and radiological data were collected on 243 patients treated between 1992 and 2015...
September 19, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28915798/vemurafenib-plus-cobimetinib-in-unresectable-stage-iiic-or-stage-iv-melanoma-response-monitoring-and-resistance-prediction-with-positron-emission-tomography-and-tumor-characteristics-reposit-study-protocol-of-a-phase-ii-open-label-multicenter-study
#16
Bernies van der Hiel, John B A G Haanen, Marcel P M Stokkel, Daniel S Peeper, Connie R Jimenez, Jos H Beijnen, Bart A van de Wiel, Ronald Boellaard, Alfons J M van den Eertwegh
BACKGROUND: In patients with BRAFV600 mutated unresectable stage IIIc or metastatic melanoma, molecular targeted therapy with combined BRAF/MEK-inhibitor vemurafenib plus cobimetinib has shown a significantly improved progression-free survival and overall survival compared to treatment with vemurafenib alone. Nevertheless, the majority of BRAFV600 mutation-positive melanoma patients will eventually develop resistance to treatment. Molecular imaging with (18)F-Fluorodeoxyglucose ((18)F-FDG) PET has been used to monitor response to vemurafenib in some BRAFV600 mutated metastatic melanoma patients, showing a rapid decline of (18)F-FDG uptake within 2 weeks following treatment...
September 15, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28894934/tumor-infiltrating-lymphocytes-in-lymph-node-metastases-of-stage-iii-melanoma-correspond-to-response-and-survival-in-nine-patients-treated-with-ipilimumab-at-the-time-of-stage-iv-disease
#17
Stefan Diem, Omar Hasan Ali, Christoph J Ackermann, David Bomze, Viktor H Koelzer, Wolfram Jochum, Daniel E Speiser, Kirsten D Mertz, Lukas Flatz
Prognosis of metastatic melanoma improved with the development of checkpoint inhibitors. The role of tumor infiltrating lymphocytes (TILs) in lymph node metastases of stage III melanoma remains unclear. We retrospectively characterized TILs in primary melanomas and matched lymph node metastases (stage III melanoma) of patients treated with the checkpoint inhibitor ipilimumab. Tumor infiltrating lymphocytes were characterized for CD3, CD4, and CD8 expressions by immunohistochemistry. 4/9 patients (44%) responded to treatment with ipilimumab (1 complete and 2 partial remissions, 1 stable disease)...
September 11, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28890210/photodynamic-therapy-an-option-in-mycosis-fungoides
#18
Pileri Alessandro, Sgubbi Paola, Agostinelli Claudio, Infusino Salvatore Domenico, Vaccari Sabina, Patrizi Annalisa
BACKGROUND: Photodynamic therapy (PDT) is a well-known and effective treatment for non-melanoma skin-cancer. Numerous studies have also shown its effectiveness in mycosis fungoides. The aim of the study was to analyse MF patients treated with PDT at the Dermatology Unit of Bologna University. METHODS: We retrospectively analysed MF patients treated with PDT over the last ten years. Each PDT protocol consisted of the appliance for 3h under an occlusive film dressing on each lesion of a one-mm-thick layer of 16% methyl aminolaevulinate (MAL) 160mg/g cream (Metvix(®), Galderma, Paris, France)...
September 7, 2017: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/28868024/isolated-splenic-metastasis-from-non-small-cell-lung-cancer-a-case-report-and-review-of-the-literature
#19
Nikolaos Mitsimponas, Maria Mitsogianni, Felipe Crespo, Karl-Axel Hartmann, Stefan Diederich, Bernd Klosterhalfen, Aristoteles Giagounidis
Metastases to the spleen are rare but have been reported for different tumor entities, including breast cancer, lung cancer, colorectal cancer, ovarian cancer, and melanoma. As an isolated event, splenic metastasis from non-small-cell lung cancer (NSCLC) is exceedingly rare. Until now, only 28 cases have been reported in the medical literature. We report the case of a 66-year-old woman with NSCLC (adenocarcinoma) who presented with a synchronous, isolated splenic metastasis. Operative removal of both primary tumor and metastasis was not possible due to multiple comorbidities...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28806256/recurrent-malignant-melanoma-detected-on-18f-fluciclovine-pet-ct-imaging-for-prostate-cancer
#20
Eugene J Teoh, Maria T Tsakok, Kevin M Bradley, Katherine Hyde, Manil Subesinghe, Fergus V Gleeson
A 66-year-old man presented with biochemical recurrence of prostate cancer and underwent F-fluciclovine PET/CT to detect sites of recurrence. He had a history of resected truncal stage IIIC malignant melanoma, with bilateral axillary node involvement on sentinel node biopsy, in complete remission for 3 years. F-fluciclovine PET/CT demonstrated an incidental fluciclovine-avid right axillary node (SUVmax = 4.3). Diagnostic sampling confirmed recurrent malignant melanoma.
October 2017: Clinical Nuclear Medicine
keyword
keyword
11576
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"